• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GERN alert in real time by email

     

    ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management.

    "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 trials this year," stated Patrick Mooney, Chief Executive Officer of SpyGlass Pharma. "Her prior experience managing multinational organizations and teams nicely complements our existing Board of Directors' strengths. We look forward to leveraging Liz's valued insights, guidance and counsel as SpyGlass advances its novel platform to reimagine glaucoma management for patients with glaucoma and other chronic eye conditions."

    "I am excited to join the SpyGlass Board of Directors as the Company prepares to initiate two pivotal Phase 3 trials in patients with moderate open-angle glaucoma or ocular hypertension," said Ms. O'Farrell. "I was immediately impressed by the compelling multi-year data already generated by SpyGlass' Drug Delivery Platform, and I look forward to utilizing my deep experience across finance and operational functions to support the SpyGlass team as they advance a longer-duration alternative for chronic ophthalmic conditions."

    Ms. O'Farrell spent the majority of her accomplished career at Eli Lilly, where she held several executive management positions including General Auditor, CFO of Lilly USA, and SVP of Policy and Finance. Prior to her retirement from Eli Lilly in 2017, she served as the Chief Procurement Officer and Head of Global Shared Services. Ms. O'Farrell's broad experience in finance includes accounting and reporting, FP&A, operational finance and audit. She currently serves as a board member and as the Audit Committee Chair of Karius Inc., Lensar Inc. (NASDAQ:LNSR) and Geron Corporation, where she also serves as Chair of the Board (NASDAQ:GERN). She also serves as board member and member of the audit and compensation committee of Genmab Corporation (NASDAQ:GMAB), providing important advisory support as the company expanded its commercial footprint in the U.S. Elizabeth earned an M.B.A. in Management Information Systems and B.A. in Accounting from Indiana University Bloomington.

    ABOUT SPYGLASS PHARMA

    The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver up to 3 years of bimatoprost to targeted tissues. Patients in the first-in-human study will continue to be followed over time, and the Company plans to share 24-month follow up data at the American Academy of Ophthalmology meeting later this year. SpyGlass completed enrollment in a Phase I/II study in the United States to investigate the safety and efficacy of its platform in a larger patient pool. SpyGlass plans to work with the U.S. Food and Drug Administration (FDA) to advance the program through Phase III clinical trials and ultimately to potential commercial approval.

    SpyGlass Pharma was co-founded by Dr. Malik Y. Kahook, M.D., and Glenn Sussman and is located in Southern California. The Company is focused on the development of the world's first, IOL-mounted, controlled release drug delivery platform capable of delivering multiple years of therapy. The technology was developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine. For more information, visit: www.spyglasspharma.com.

    Media Contact:

    Nami Surendranath

    +1(212) 418-8981

    [email protected]

    Investor Contact:

    Ami Bavishi

    [email protected]

    Nick Colangelo

    [email protected]



    Primary Logo

    Get the next $GERN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GERN
    $GMAB
    $LNSR

    CompanyDatePrice TargetRatingAnalyst
    Genmab A/S
    $GMAB
    9/23/2025$43.00Neutral → Buy
    Guggenheim
    Geron Corporation
    $GERN
    7/10/2025$1.00Sell
    Goldman
    Geron Corporation
    $GERN
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    Genmab A/S
    $GMAB
    4/1/2025Mkt Perform → Underperform
    Bernstein
    Genmab A/S
    $GMAB
    3/11/2025Mkt Perform → Outperform
    William Blair
    Geron Corporation
    $GERN
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    Geron Corporation
    $GERN
    2/26/2025Buy → Neutral
    H.C. Wainwright
    Genmab A/S
    $GMAB
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $GERN
    $GMAB
    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    5/13/25 4:20:43 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Legal Officer Samuels Scott Alan bought $24,150 worth of shares (15,000 units at $1.61), increasing direct ownership by 128% to 26,682 units (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    3/3/25 6:01:08 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, President and CEO Scarlett John A bought $22,062 worth of shares (12,500 units at $1.76) (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    3/3/25 6:01:06 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $GMAB
    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Genmab upgraded by Guggenheim with a new price target

    Guggenheim upgraded Genmab from Neutral to Buy and set a new price target of $43.00

    9/23/25 7:47:11 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Geron with a new price target

    Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00

    7/10/25 8:55:29 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron downgraded by Scotiabank with a new price target

    Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

    5/8/25 8:26:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $GMAB
    $LNSR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    6/7/24 12:36:59 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $GMAB
    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP, Chief Commercial Officer Elnawawi Ahmed

    4 - GERON CORP (0000886744) (Issuer)

    10/20/25 5:35:05 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Elnawawi Ahmed claimed ownership of 10,000 shares (SEC Form 3)

    3 - GERON CORP (0000886744) (Issuer)

    10/20/25 5:07:28 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Spiegel Robert J. was granted 5,702 shares, increasing direct ownership by 3% to 188,546 units (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    10/1/25 4:38:06 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $GMAB
    $LNSR
    SEC Filings

    View All

    LENSAR Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events

    8-K - LENSAR, Inc. (0001320350) (Filer)

    10/21/25 4:30:26 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    10/16/25 7:30:43 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Geron Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GERON CORP (0000886744) (Filer)

    10/14/25 8:16:36 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $GMAB
    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025, covering an aggregate of 1,579,500 shares of its common stock, consisting of stock options to purchase an aggregate of 1,553,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 26,500 shares of common stock, to three newly hired employees and (ii) October 20, 2025, covering an aggregate of 1,500,000 shares of its common stock to one newly hired employee, each as an inducement material to their acceptance of employment with Geron. The stock options granted on October 17, 2025 have an exercise price

    10/20/25 5:32:00 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

    Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expression A Phase 3 trial in endometrial cancer is underway U.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer Genmab A/S (NASDAQ:GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year,

    10/18/25 6:00:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

    Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,672 million in the third quarter of 2025. Net trade sales were USD 2,088 million in the U.S. and USD 1,584 million in the rest of the world. Genmab receives royalties on the

    10/14/25 6:23:01 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $GMAB
    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 5:46:12 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 9:31:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $GMAB
    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    Geron Corporation Announces Executive Leadership Transitions and Appointments

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2012 and has served as Executive Vice President, Chief Operating Officer since January 2019, will depart the company on October 15, 2025, transitioning to a consulting role, while pursuing other interests. Jim Ziegler, who joined the company in September 2024 as Executive Vice President, Chief Commer

    10/13/25 4:34:48 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Geron Appoints Harout Semerjian as President and Chief Executive Officer

    Industry veteran brings 30+ years of commercial hematology and oncology experience to help accelerate Geron's next phase of growth Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Harout Semerjian as President and Chief Executive Officer (CEO) and a member of the Board of Directors, effective tomorrow. Mr. Semerjian will succeed Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Ms. Bir will continue in her role on Geron's Board of Directors, where she will contribute her insight and strategic counsel. "Our Board conducted an extens

    8/6/25 7:00:00 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $GMAB
    $LNSR
    Financials

    Live finance-specific insights

    View All

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million. The increase corresponds to approximately 0.01% of the company's share capital. The new shares are ordinary shares without any special rights and are freely tra

    8/12/25 2:36:02 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care